Answers are grounded in this paper and cite their sources.
Most new cancer therapies were approved first by the FDA, and delays in submission of regulatory applications accounted for substantial delays in approving cancer drugs in other countries. Regulators should prioritize faster review for drugs with high clinical benefit.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: